[
  {
    "ts": "2026-01-14T08:30:00+00:00",
    "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
    "url": "https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b15c25b0-c7a0-3818-934e-6ce6fa9019c6",
      "content": {
        "id": "b15c25b0-c7a0-3818-934e-6ce6fa9019c6",
        "contentType": "STORY",
        "title": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
        "pubDate": "2026-01-14T08:30:00Z",
        "displayTime": "2026-01-14T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CGEM"
            },
            {
              "symbol": "MGNX"
            },
            {
              "symbol": "XNCR"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T04:32:59+00:00",
    "headline": "3 S&P 500 Stocks Walking a Fine Line",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finance.yahoo.com/news/3-p-500-stocks-walking-043259652.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "6eb451c6-740a-30aa-821c-df33415176f3",
      "content": {
        "id": "6eb451c6-740a-30aa-821c-df33415176f3",
        "contentType": "STORY",
        "title": "3 S&P 500 Stocks Walking a Fine Line",
        "description": "",
        "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
        "pubDate": "2026-01-14T04:32:59Z",
        "displayTime": "2026-01-14T04:32:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/a5ad0705f67a910204b9dccbf5099673",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BLDR Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/82ojwT31gBQ.EkdRVvMVPg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/a5ad0705f67a910204b9dccbf5099673.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qBMIRHxWMdYsUG3N4pyu7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/a5ad0705f67a910204b9dccbf5099673.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-p-500-stocks-walking-043259652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-p-500-stocks-walking-043259652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AME"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "BLDR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T13:00:17+00:00",
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet",
    "summary": "The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-130017110.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5980186c-c2c2-3903-927e-2afdebce0965",
      "content": {
        "id": "5980186c-c2c2-3903-927e-2afdebce0965",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet",
        "description": "",
        "summary": "The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...",
        "pubDate": "2026-01-14T13:00:17Z",
        "displayTime": "2026-01-14T13:00:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-130017110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-130017110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T13:00:00+00:00",
    "headline": "BioCT Appoints Four Distinguished Life Sciences Leaders to Board of Directors",
    "summary": "NEW HAVEN, Conn., January 14, 2026--BioCT, Connecticut’s life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Jennifer Good, Co-Founder, President, and Chief Execu",
    "url": "https://finance.yahoo.com/news/bioct-appoints-four-distinguished-life-130000613.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "952c2f2e-36e0-3367-bf97-9ec0a5732496",
      "content": {
        "id": "952c2f2e-36e0-3367-bf97-9ec0a5732496",
        "contentType": "STORY",
        "title": "BioCT Appoints Four Distinguished Life Sciences Leaders to Board of Directors",
        "description": "",
        "summary": "NEW HAVEN, Conn., January 14, 2026--BioCT, Connecticut’s life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Jennifer Good, Co-Founder, President, and Chief Execu",
        "pubDate": "2026-01-14T13:00:00Z",
        "displayTime": "2026-01-14T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/b1137f12cb76822571b5b1bbd1ba4e4a",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VCii4LFwOn8L.c6datZEwg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b1137f12cb76822571b5b1bbd1ba4e4a.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o1jOSnPJzmHhWPtSjqSB.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b1137f12cb76822571b5b1bbd1ba4e4a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bioct-appoints-four-distinguished-life-130000613.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bioct-appoints-four-distinguished-life-130000613.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TRVI"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:16:14+00:00",
    "headline": "Bristol Myers price target raised to $60 from $54 at Leerink",
    "summary": "Leerink analyst David Risinger raised the firm’s price target on Bristol Myers (BMY) to $60 from $54 and keeps an Outperform rating on the shares. The firm sees significant pipeline optionality in 2026 and thus room for additional stock upside potential. Leerink notes the company provided an overview of its pipeline readouts to watch in 2026 and beyond at a conference on January 12, 2026. The company has 12 registrational data readouts from 8 assets anticipated in 2026, most of which represent s",
    "url": "https://finance.yahoo.com/news/bristol-myers-price-target-raised-141614863.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "5cb4c93d-7728-36c1-b9eb-f26f28e07bed",
      "content": {
        "id": "5cb4c93d-7728-36c1-b9eb-f26f28e07bed",
        "contentType": "STORY",
        "title": "Bristol Myers price target raised to $60 from $54 at Leerink",
        "description": "",
        "summary": "Leerink analyst David Risinger raised the firm’s price target on Bristol Myers (BMY) to $60 from $54 and keeps an Outperform rating on the shares. The firm sees significant pipeline optionality in 2026 and thus room for additional stock upside potential. Leerink notes the company provided an overview of its pipeline readouts to watch in 2026 and beyond at a conference on January 12, 2026. The company has 12 registrational data readouts from 8 assets anticipated in 2026, most of which represent s",
        "pubDate": "2026-01-14T14:16:14Z",
        "displayTime": "2026-01-14T14:16:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/b283ad7faa9680c3e9623f6536014bcd",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/bristol-myers-price-target-raised-to-60-from-54-at-leerink-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L_QzXFOw6tvO2n9ieo4KMw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/b283ad7faa9680c3e9623f6536014bcd.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XA3lrHwh5F9JVuBl4VtAAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/b283ad7faa9680c3e9623f6536014bcd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-price-target-raised-141614863.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-price-target-raised-141614863.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T16:20:00+00:00",
    "headline": "Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica",
    "summary": "The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is propelled by a combination of unprecedented financial investment, a rich pipeline of novel therapies, and expanding treatment infrastructure across key geographies.Chicago, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The global central nervous system therapeutic market was valued at 129.38 billion in 2024 and is expected to reach US$ 235.87 billion by 2033, growing at a CAGR of 6.90%",
    "url": "https://finance.yahoo.com/news/central-nervous-system-therapeutic-market-162000161.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ba7a9528-1fd4-37e8-9066-61a8f1dc30c6",
      "content": {
        "id": "ba7a9528-1fd4-37e8-9066-61a8f1dc30c6",
        "contentType": "STORY",
        "title": "Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica",
        "description": "",
        "summary": "The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is propelled by a combination of unprecedented financial investment, a rich pipeline of novel therapies, and expanding treatment infrastructure across key geographies.Chicago, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The global central nervous system therapeutic market was valued at 129.38 billion in 2024 and is expected to reach US$ 235.87 billion by 2033, growing at a CAGR of 6.90%",
        "pubDate": "2026-01-14T16:20:00Z",
        "displayTime": "2026-01-14T16:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/central-nervous-system-therapeutic-market-162000161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/central-nervous-system-therapeutic-market-162000161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:35:00+00:00",
    "headline": "Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?",
    "summary": "Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.",
    "url": "https://finance.yahoo.com/news/keytruda-continue-aid-mercks-top-143500090.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cdb30359-1b2b-31fa-b609-5b2219367f21",
      "content": {
        "id": "cdb30359-1b2b-31fa-b609-5b2219367f21",
        "contentType": "STORY",
        "title": "Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?",
        "description": "",
        "summary": "Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.",
        "pubDate": "2026-01-14T14:35:00Z",
        "displayTime": "2026-01-14T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EfDoN3QVRYGCfRDweFAACw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JwDxubmjtiCRyiYBqVh9AQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-continue-aid-mercks-top-143500090.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-continue-aid-mercks-top-143500090.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]